Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTRN | P46939 | 9/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.77 |
| ▸ | AHR | P35869 | 1/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.77 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.56 |
| ▸ | CETP | P11597 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ezutromid SCHEMBL31080435 | 0.87 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| Ezutromid SCHEMBL732212 | 0.87 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| Ezutromid SCHEMBL29376738 | 0.87 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| Ezutromid SCHEMBL30791155 | 0.87 | UTRN (1.00) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2246048 | 0.85 | UTRN (0.74) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2245790 | 0.82 | UTRN (0.77) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2243039 | 0.81 | UTRN (0.77) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2243160 | 0.81 | UTRN (0.72) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2244375 | 0.80 | UTRN (0.71) | UTRNCYP1A2AHRHDAC6MAOB | |
| SCHEMBL2245091 | 0.80 | UTRN (0.78) | UTRNCYP1A2AHRHDAC6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343807-B1 | DIARYL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITS C VIRUS | SCHERING CORP (US) | 2009-04-29 | — | — | EP | disclosed |
| WO-2009021750-A2 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2009-02-19 | — | — | WO | disclosed |
| US-6911428-B2 | Viricides | SCHERING CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1343807-A2 | DIARYL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITS C VIRUS | SCHERING CORPORATION (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020147139-A1 | Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2002-10-10 | — | — | US | disclosed |
| WO-2002048172-A2 | DIARYL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITS C VIRUS | SCHERING CORPORATION (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147139-A1 | Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus | PRSS1, PEPD, TMPRSS11D | UTRN 3665/4885CYP1A2 1259/4885AHR 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.